PMV Pharmaceuticals, Inc.

PMVPSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1699382

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$55.9M	$52.0M	$36.5M	$23.9M	$20.8M
Operating Expenses	$80.1M	$77.0M	$58.3M	$34.9M	$26.6M
Operating Income (Loss)	-$80.1M	-$77.0M	-$58.3M	-$34.9M	-$26.6M
Other Nonoperating Income (Expense)	$11.2M	$3.7M	$470.0K	$508.0K	$1.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$69.0M	-$73.3M	-$57.8M	-$34.4M	-$25.3M
Income Tax Expense (Benefit)	$2.0K	-$9.0K	$23.0K	$6.0K	$8.0K
Net Income (Loss) Attributable to Parent	-$69.0M	-$73.3M	-$57.8M	-$34.4M	-$25.4M
Earnings Per Share, Basic	-$1.44	-$1.61	-$1.28	-$2.40	—
Earnings Per Share, Diluted	-$1.44	-$1.61	-$1.28	-$2.40	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$191.3M	$252.2M	$270.3M	$331.6M	$365.5M
Assets, Current	$175.7M	$207.4M	$247.0M	$301.3M	$364.8M
Cash and Cash Equivalents, at Carrying Value	$40.9M	$37.7M	$108.3M	$172.5M	$361.4M
Liabilities	$15.2M	$26.5M	$24.3M	$23.0M	$6.4M
Liabilities, Current	$14.4M	$14.0M	$10.8M	$12.2M	$6.4M
Accounts Payable, Current	$6.6M	$3.2M	$3.0M	$3.2M	$1.6M
Stockholders' Equity Attributable to Parent	$246.0M	$308.6M	$359.1M	-$70.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$55.7M	-$63.8M	-$46.6M	-$32.7M	-$22.1M
Net Cash Provided by (Used in) Investing Activities	-$50.5M	-$1.4M	-$143.6M	$27.9M	$3.2M
Net Cash Provided by (Used in) Financing Activities	$35.6M	$958.0K	$2.0M	$293.0M	$61.8M
Payments to Acquire Property, Plant, and Equipment	$962.0K	$8.0M	$1.3M	$148.0K	$109.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)